Cassava Sciences Shares Experience Dramatic Volatility Following CEO’s Major Investment

The shares of Cassava Sciences demonstrated extreme price swings over the past week, culminating in a Friday decline of 3.55% to close at $2.99. This pullback, however, followed a spectacular mid-week surge where the stock skyrocketed by 46.98% in a single session. The dramatic upward move was primarily fueled by significant share purchases made by the company’s chief executive.

CEO’s Substantial Purchases Signal Confidence

President and CEO Richard Barry provided a powerful vote of confidence through aggressive insider buying. Between September 18th and 19th, Barry acquired a total of 237,941 shares, representing an investment of approximately $534,743. These transactions occurred at prices ranging from $2.13 to $2.29 per share. Additional purchases followed on September 22nd. Market participants interpreted these substantial acquisitions as a clear demonstration of management’s belief in the company’s prospects, particularly given recent operational challenges.

Strategic Pivot for Simufilam Program

This wave of optimistic sentiment arrives as Cassava Sciences executes a strategic repositioning of its drug candidate Simufilam. Following the discontinuation of its development for Alzheimer’s disease after disappointing Phase 3 trial results, the company is now focusing on a new therapeutic application. Promising preclinical data released in June 2025 indicated a substantial 60% reduction in seizure frequency in mouse models for the treatment of epilepsy associated with tuberous sclerosis. Initial human trials for this new indication are scheduled to commence in the first half of 2026.

Should investors sell immediately? Or is it worth buying Cassava Sciences?

Financial Health and Forward Outlook

As of June 30, 2025, Cassava Sciences maintained a solid financial position with $112.4 million in cash reserves and no outstanding debt. Management projects available liquid resources to be between $61 million and $65 million by the conclusion of 2025. This financial cushion is considered essential for funding the next development stage of the repurposed Simufilam program.

Despite the recent downward movement at week’s end, the equity has still delivered impressive returns over a broader timeframe, showing a 41.71% gain across a two-week period. Market observers have identified several upcoming catalysts, including the planned initiation of human studies in 2026 and the forthcoming third-quarter earnings report scheduled for November 6th.